Frontiers in immunology · 2025
Outcomes and risk factors of COVID-19 in patients with bullous pemphigoid: a cross-sectional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yuexin, Huang Dawei, Shi Yuling, Ding Yangfeng, Gao Yunlu
Аннотация
BACKGROUND: The outcomes of coronavirus disease 2019 (COVID-19) in patients with bullous pemphigoid (BP) remain insufficiently understood. This study aimed to evaluate the impact of COVID-19 on BP patients and identify factors influencing the risk and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in BP patients.
METHODS: A cross-sectional survey was conducted among BP patients in the Department of Dermatology at Shanghai Skin Disease Hospital from December 1, 2022, to March 1, 2023. Participants completed a comprehensive questionnaire addressing demographics, medical conditions, clinical symptoms, and behaviors during the COVID-19 pandemic. Factors influencing the risk of SARS-CoV-2 infection and its severity were evaluated by logistic regression.
RESULTS: A total of 96 BP patients were analyzed. Demographic and clinical profiles, COVID-19-related characteristics, and the pandemic's impact on healthcare-seeking behaviors were described. Our findings showed that vaccination was associated with a reduced risk of SARS-CoV-2 infection (odds ratio [OR]: 0.157, 95% confidence interval [CI]: 0.045-0.552, p=0.002) and infection severity (OR: 0.044, 95% CI: 0.004-0.544, p=0.015). Furthermore, the use of prednisone at a dose >10 mg/day in the last 3 months was associated with an increased risk of SARS-CoV-2 infection (OR: 7.911, 95% CI: 1.379-45.393, p=0.012) but did not appear to influence infection severity.
CONCLUSIONS: The COVID-19 pandemic posed significant challenges for BP patients. Our study found that the use of prednisone at a dose >10 mg/day in the last three months was associated with an increased risk of SARS-CoV-2 infection. Vaccination provided protection against SARS-CoV-2 infection and severe COVID-19 in BP patients.
METHODS: A cross-sectional survey was conducted among BP patients in the Department of Dermatology at Shanghai Skin Disease Hospital from December 1, 2022, to March 1, 2023. Participants completed a comprehensive questionnaire addressing demographics, medical conditions, clinical symptoms, and behaviors during the COVID-19 pandemic. Factors influencing the risk of SARS-CoV-2 infection and its severity were evaluated by logistic regression.
RESULTS: A total of 96 BP patients were analyzed. Demographic and clinical profiles, COVID-19-related characteristics, and the pandemic's impact on healthcare-seeking behaviors were described. Our findings showed that vaccination was associated with a reduced risk of SARS-CoV-2 infection (odds ratio [OR]: 0.157, 95% confidence interval [CI]: 0.045-0.552, p=0.002) and infection severity (OR: 0.044, 95% CI: 0.004-0.544, p=0.015). Furthermore, the use of prednisone at a dose >10 mg/day in the last 3 months was associated with an increased risk of SARS-CoV-2 infection (OR: 7.911, 95% CI: 1.379-45.393, p=0.012) but did not appear to influence infection severity.
CONCLUSIONS: The COVID-19 pandemic posed significant challenges for BP patients. Our study found that the use of prednisone at a dose >10 mg/day in the last three months was associated with an increased risk of SARS-CoV-2 infection. Vaccination provided protection against SARS-CoV-2 infection and severe COVID-19 in BP patients.